Mei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mei Li has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Ning Gu
School of Biomedical Engineering and Informatics, Nanjing Medical University, Jiangsu Key Laboratory for Biomedical Electromagnetic Precision Theranostics, Nanjing 210029, China; Nanjing Key Laboratory for Cardiovascular Information and Health, Engineering Medicine Institute of Clinical Medicine, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China
3 shared publications - Benhui Hu
School of Biomedical Engineering and Informatics Nanjing Medical University Nanjing 211166 China
2 shared publications Gaoxin Zhou
Key Laboratory for Bio-Electromagnetic Environment and Advanced Medical Theranostics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China
2 shared publicationsYipin Wang
National Demonstration Center for Experimental Basic Medical Education, Nanjing Medical University, Nanjing 211166, China
2 shared publicationsBiao Xu
Department of Cardiology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing 210008, China
1 shared publicationBin Huang
Key Laboratory for Bio-Electromagnetic Environment and Advanced Medical Theranostics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China
1 shared publication
Latest Publications
- Open Access
- 10 October 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 190, 107-119
Tuning interfacial molecular asymmetry to engineer protective coatings with superior surface anchoring, antifouling and antibacterial properties
- 10 October 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 190, 107-119
Open AccessTuning interfacial molecular asymmetry to engineer protective coatings with superior surface anchoring, antifouling and antibacterial properties
- 16 January 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (4) , 3073-3086
A Self-Homing and Traceable Cardiac Patch Leveraging Ferumoxytol for Spatiotemporal Therapeutic Delivery
Mesenchymal stem cell (MSC)-based cardiac patches are envisioned to be a promising treatment option for patients with myocardial infarction. However, their therapeutic efficacy and duration are hampered due to their limited retention on the epicardium. We engineered a scaffold-free MSC sheet with an inherent ability to migrate into the infarcted myocardium, a strategy enabled by actively establishing a sustained intracellular hypoxic environment through the endocytosis of our FDA-approved ferumoxytol. This iron oxide nanoparticle stabilized hypoxia-induced factor-1α, triggering upregulation of the CXC chemokine receptor and subsequent MSC chemotaxis. Thus, MSCs integrated into 2/3 depth of the left ventricular anterior wall in a rat model of acute myocardial infarction and persisted for at least 28 days. This led to spatiotemporal delivery of paracrine factors by MSCs, enhancing cardiac regeneration and function. Ferumoxytol also facilitated the noninvasive MRI tracking of implanted MSCs. Our approach introduces a strategy for mobilizing MSC migration, holding promise for rapid clinical translation in myocardial infarction treatment.
- 16 January 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (4) , 3073-3086
A Self-Homing and Traceable Cardiac Patch Leveraging Ferumoxytol for Spatiotemporal Therapeutic Delivery
Mesenchymal stem cell (MSC)-based cardiac patches are envisioned to be a promising treatment option for patients with myocardial infarction. However, their therapeutic efficacy and duration are hampered due to their limited retention on the epicardium. We engineered a scaffold-free MSC sheet with an inherent ability to migrate into the infarcted myocardium, a strategy enabled by actively establishing a sustained intracellular hypoxic environment through the endocytosis of our FDA-approved ferumoxytol. This iron oxide nanoparticle stabilized hypoxia-induced factor-1α, triggering upregulation of the CXC chemokine receptor and subsequent MSC chemotaxis. Thus, MSCs integrated into 2/3 depth of the left ventricular anterior wall in a rat model of acute myocardial infarction and persisted for at least 28 days. This led to spatiotemporal delivery of paracrine factors by MSCs, enhancing cardiac regeneration and function. Ferumoxytol also facilitated the noninvasive MRI tracking of implanted MSCs. Our approach introduces a strategy for mobilizing MSC migration, holding promise for rapid clinical translation in myocardial infarction treatment.
- 20 October 2023
- Published by Elsevier in Biomaterials
- Vol. 302, 122361
Mixed-valence gold-porphyrin two-dimensional coordination networks for repurposing of chrysotherapy
- 20 October 2023
- Published by Elsevier in Biomaterials
- Vol. 302, 122361
Mixed-valence gold-porphyrin two-dimensional coordination networks for repurposing of chrysotherapy
- Open Access
Recent fabrications and applications of cardiac patch in myocardial infarction treatment
Myocardial infarction caused by coronary artery obstruction results in the loss of heart muscle, which is subsequently replaced by scar tissue with limited therapeutic options. Cardiac patch based therapy has emerged as a promising strategy for the treatment of severe myocardial infarction. They are designed to be attached to the surface of the heart, that is, they are meant to “patch” the injured heart, thus restoring the damaged or failing myocardium locally through mechanical and regeneration support. The engineered three‐dimension cardiac patch is composed of biomaterial scaffolds with/without cells or inducible factors, which is typically manufactured by decellularize extracellular matrix, electrospinning, three‐dimension printing, hydrogels, or by stacking cell sheets. In this review, we outline the latest advances of the construction methods and beneficial effects of cardiac patches used in animal and clinical treatment of cardiovascular diseases, especially in myocardial infarction. We discuss the cell souring of cell‐based patches, the types of biomolecules for cell‐free patches, and their engineering methods. In addition, the method of implanting the cardiac patch to the injured heart is also described. Finally, we briefly outlook the future challenges and probable solutions in this area.
Open AccessRecent fabrications and applications of cardiac patch in myocardial infarction treatment
Myocardial infarction caused by coronary artery obstruction results in the loss of heart muscle, which is subsequently replaced by scar tissue with limited therapeutic options. Cardiac patch based therapy has emerged as a promising strategy for the treatment of severe myocardial infarction. They are designed to be attached to the surface of the heart, that is, they are meant to “patch” the injured heart, thus restoring the damaged or failing myocardium locally through mechanical and regeneration support. The engineered three‐dimension cardiac patch is composed of biomaterial scaffolds with/without cells or inducible factors, which is typically manufactured by decellularize extracellular matrix, electrospinning, three‐dimension printing, hydrogels, or by stacking cell sheets. In this review, we outline the latest advances of the construction methods and beneficial effects of cardiac patches used in animal and clinical treatment of cardiovascular diseases, especially in myocardial infarction. We discuss the cell souring of cell‐based patches, the types of biomolecules for cell‐free patches, and their engineering methods. In addition, the method of implanting the cardiac patch to the injured heart is also described. Finally, we briefly outlook the future challenges and probable solutions in this area.
- Open Access
- 7 June 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 91 (7) , 660-665
Phacoemulsification combined with posterior capsulorhexis and anterior vitrectomy in the management of malignant glaucoma in phakic eyes
Purpose: To describe sequential phacoemulsification–intraocular lens (IOL) implantation–posterior capsulorhexis–anterior vitrectomy in the management of phakic malignant glaucoma. Methods: Twenty consecutive patients (25 eyes) with phakic malignant glaucoma were enrolled at the Zhongshan Ophthalmic Center, Sun Yat-sen University. All patients underwent phacoemulsification, IOL implantation and posterior capsulorhexis together with anterior vitrectomy via a clear corneal paracentesis. Visual acuity, intraocular pressure (IOP), anterior chamber depth (ACD), surgical complications and medications required after the surgery were recorded. Results: After surgery, the mean LogMAR visual acuity and ACD increased significantly (visual acuity from −1.56 ± 1.17 to −0.54 ± 0.81, p < 0.001; ACD from 0.367 ± 0.397 mm to 2.390 ± 0.575 mm, p < 0.001), and mean IOP decreased significantly (from 39.6 ± 10.6 mm Hg to 14.5 ± 4.1 mmHg, p < 0.001). No serious perioperative complications occurred, and only five eyes required topical glaucoma medications after surgery. Conclusion: Combined phacoemulsification–IOL implantation–posterior capsulorhexis–anterior vitrectomy surgery is a safe and effective method for treating patients with phakic malignant glaucoma.
- 7 June 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 91 (7) , 660-665
Open AccessPhacoemulsification combined with posterior capsulorhexis and anterior vitrectomy in the management of malignant glaucoma in phakic eyes
Purpose: To describe sequential phacoemulsification–intraocular lens (IOL) implantation–posterior capsulorhexis–anterior vitrectomy in the management of phakic malignant glaucoma. Methods: Twenty consecutive patients (25 eyes) with phakic malignant glaucoma were enrolled at the Zhongshan Ophthalmic Center, Sun Yat-sen University. All patients underwent phacoemulsification, IOL implantation and posterior capsulorhexis together with anterior vitrectomy via a clear corneal paracentesis. Visual acuity, intraocular pressure (IOP), anterior chamber depth (ACD), surgical complications and medications required after the surgery were recorded. Results: After surgery, the mean LogMAR visual acuity and ACD increased significantly (visual acuity from −1.56 ± 1.17 to −0.54 ± 0.81, p < 0.001; ACD from 0.367 ± 0.397 mm to 2.390 ± 0.575 mm, p < 0.001), and mean IOP decreased significantly (from 39.6 ± 10.6 mm Hg to 14.5 ± 4.1 mmHg, p < 0.001). No serious perioperative complications occurred, and only five eyes required topical glaucoma medications after surgery. Conclusion: Combined phacoemulsification–IOL implantation–posterior capsulorhexis–anterior vitrectomy surgery is a safe and effective method for treating patients with phakic malignant glaucoma.